2016 Archived Content

October 31 - November 1

High-Content Analysis

3D Cell Culture: Organoid, Spheroid & Organ-on-a-Chip Models

November 1 - 2

Phenotypic Screening

Screening & Functional Analysis of 3D Models


Coverage Includes:

  • High-Content Screening of 3D Models
  • Spheroid Models for Drug Screening
  • High-Content Phenotypic Screening
  • HCS Image Analysis and Modeling
  • Phenotypic Screening in Human iPSC Models
  • Organoids and Organotypic Cell Culture
  • Organ-on-a-Chip
  • Case Studies in Phenotypic Screening
  • 3D Models for Oncology Drug Screening
  • Patient-Derived Tumor Models for Screening
  • Phenotypic Screening of 3D Models
  • Quantitative Systems Pharmacology

 Dinner Short Courses:



Keynote Presenters

Stuart SchreiberStuart Schreiber
Director, Center for the Science of Therapeutics, Broad Institute 

Jeremy JenkinsJeremy L. Jenkins
Director, Molecular Pathways, Novartis  

David SwinneyDavid C. Swinney
CEO, Institute for Rare and Neglected Diseases Drug Discovery (iRND3) 

Lansing TaylorD. Lansing Taylor
Director, University of Pittsburgh Drug Discovery Institute 

About the Event

Cambridge Healthtech Institute is pleased to bring the longest-running High-Content Analysis & 3D Screening Conference to the hub of biotech and pharmaceutical research - Cambridge, MA. Now in its 14th year, the event explores the next generation in high-content and phenotypic screening and takes it to the third dimension. The High-Content Analysis and Phenotypic Screening stream will focus on the latest advancements in HCA technologies and applications, including phenotypic and high-content screening of 3D models, HCS image analysis and modeling, screening in physiologically-relevant cellular models, and case studies and strategies for successful phenotypic drug discovery. You can also join the expanded 3-day coverage on 3D cellular models and 3D screening at the concurrent stream, which features the latest spheroid, organoid and organotypic cell culture, and organ-on-a-chip technologies; patient-derived tumor models and human iPSC models for drug screening; and case studies in oncology drug discovery using 3D cellular models. Please join us at CHI’s longest-running event dedicated to cutting-edge cellular screening!